Amit Dipak Amin
Overview
Explore the profile of Amit Dipak Amin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Filliol A, Saito Y, Nair A, Dapito D, Yu L, Ravichandra A, et al.
Nature
. 2022 Oct;
610(7931):356-365.
PMID: 36198802
Hepatocellular carcinoma (HCC), the fourth leading cause of cancer mortality worldwide, develops almost exclusively in patients with chronic liver disease and advanced fibrosis. Here we interrogated functions of hepatic stellate...
12.
Biermann J, Melms J, Amin A, Wang Y, Caprio L, Karz A, et al.
Cell
. 2022 Jul;
185(14):2591-2608.e30.
PMID: 35803246
Melanoma brain metastasis (MBM) frequently occurs in patients with advanced melanoma; yet, our understanding of the underlying salient biology is rudimentary. Here, we performed single-cell/nucleus RNA-seq in 22 treatment-naive MBMs...
13.
Melms J, Biermann J, Huang H, Wang Y, Nair A, Tagore S, et al.
Nature
. 2021 Oct;
598(7882):E2.
PMID: 34625743
No abstract available.
14.
Melms J, Biermann J, Huang H, Wang Y, Nair A, Tagore S, et al.
Nature
. 2021 Apr;
595(7865):114-119.
PMID: 33915568
Respiratory failure is the leading cause of death in patients with severe SARS-CoV-2 infection, but the host response at the lung tissue level is poorly understood. Here we performed single-nucleus...
15.
Rajan S, Amin A, Li L, Rolland D, Li H, Kwon D, et al.
Oncogene
. 2019 Dec;
39(10):2103-2117.
PMID: 31804622
Rational new strategies are needed to treat tumors resistant to kinase inhibitors. Mechanistic studies of resistance provide fertile ground for development of new approaches. Cancer drug addiction is a paradoxical...
16.
Sundara Rajan S, Li L, Kweh M, Kunkalla K, Amin A, Agarwal N, et al.
Blood Adv
. 2019 Jun;
3(12):1788-1794.
PMID: 31189527
No abstract available.
17.
Amin A, Peters T, Li L, Sundara Rajan S, Choudhari R, Puvvada S, et al.
Cold Spring Harb Mol Case Stud
. 2017 May;
3(3):a001719.
PMID: 28487884
Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of subentities. Despite ongoing explosions of data illuminating disparate...
18.
Liu G, Pei F, Yang F, Li L, Amin A, Liu S, et al.
Int J Mol Sci
. 2017 Feb;
18(2).
PMID: 28208579
Non-small-cell lung cancer (NSCLC) constitutes 85% of all lung cancers, and is the leading cause of cancer-related death worldwide. The poor prognosis and resistance to both radiation and chemotherapy warrant...
19.
Amin A, Li L, Rajan S, Gokhale V, Groysman M, Pongtornpipat P, et al.
Oncotarget
. 2016 Mar;
7(17):23715-29.
PMID: 27009859
The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and...
20.
Amin A, Rajan S, Groysman M, Pongtornpipat P, Schatz J
Biomark Cancer
. 2015 Dec;
7(Suppl 2):25-32.
PMID: 26688666
Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel...